Conference Presentation, Fireside Chat, Interview
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
- Alnylam Pharmaceuticals leverages RNA interference (RNAi) to target 100% of the human genome, a capability surpassing small molecules and biologics which address approximately 25%.
- The company achieved a 55% clinical success rate for its pipeline, significantly outperforming the industry average of 6% to 8% for other modalities.
- Alnylam has successfully delivered six approved medicines within a six-year window, driven by a proven liver-targeting delivery platform developed over a 10-year research effort.
- The company recently secured regulatory approval for Amvutra (vutrisiran) to treat hereditary transthyretin-mediated amyloidosis (hATTR), a disease affecting approximately 300,000 patients globally.
- Alnylam targets a multi-billion dollar market opportunity with hATTR treatment and is expanding its pipeline into more common diseases, including hypertension affecting 60 million people worldwide.
- CEO Yvonne Greenstreet set a five-year strategic goal in 2021 to become a top-five biotech company, targeting sustainable non-GAAP profitability by the end of the current year.
- The company plans to advance 25 clinical programs by 2025, with a specific long-term goal to deliver RNAi therapeutics to every major tissue in the body by 2030, including the central nervous system (CNS).
- Alnylam utilizes AI and AlphaFold to accelerate drug design and overcome delivery challenges to new tissues, aiming to shorten the traditional decade-plus development timeline.
- The firm has raised $8 billion over 22 years to de-risk development, focusing on genetic targets and early-stage validation to mitigate the high costs of clinical progression.
- Culture is identified as a "secret sauce" for retention and innovation, with values prioritizing teamwork, diversity of thought, and a patient-first mindset that includes mandatory patient vignettes at every board meeting.
- Greenstreet transitioned from clinical obstetrics to the biopharma industry after recognizing an MBA could amplify patient impact from hundreds to millions, a mission she continues to drive as CEO.
- Despite being named Goldman Sachs' 2024 Talks at GS participant, Greenstreet noted the persistence of gender assumptions in leadership, citing instances where her CFO was assumed to be the CEO.
- The company's mentorship philosophy emphasizes enabling leaders to grow into their authentic selves rather than molding them into predecessors, aligning with broader industry diversity goals.
- Alnylam's culture has remained consistent over two decades, explicitly integrating values of excellence, integrity, and inclusivity to maintain focus as the workforce scales to approximately 2,500 employees.